Known targets — ChEMBL curated mechanism
GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BM
The experimentally established mechanism targets of Amantadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.59 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.59 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.59 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.59 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.59 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.59 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.59 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | STAT6 | P42226 | 1/20 | 0.59 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amantadine SCHEMBL31756726 | 1.00 | THRB (1.00) | THRBCYP2C9TSHRLMNASLC22A2 | |
| Amantadine SCHEMBL4339906 | 0.85 | THRB (0.74) | THRBCYP2C9TSHRLMNASLC22A2 | |
| Amantadine SCHEMBL15015750 | 0.83 | THRB (0.71) | THRBCYP2C9TSHRLMNASLC22A2 | |
| Amantadine SCHEMBL15015696 | 0.81 | LMNA (0.70) | THRBCYP2C9TSHRLMNASLC22A2 | |
| Amantadine SCHEMBL20357994 | 0.81 | THRB (0.68) | THRBCYP2C9TSHRLMNASLC22A2 | |
| Amantadine SCHEMBL27677379 | 0.81 | THRB (0.68) | THRBCYP2C9TSHRLMNASLC22A2 | |
| Amantadine SCHEMBL15016083 | 0.79 | LMNA (0.67) | THRBCYP2C9TSHRLMNASLC22A2 | |
| Amantadine SCHEMBL20357966 | 0.79 | THRB (0.65) | THRBCYP2C9TSHRLMNASLC22A2 | |
| Amantadine SCHEMBL27937593 | 0.78 | GRIN2D (0.68) | THRBCYP2C9TSHRLMNASLC22A2 | |
| Amantadine SCHEMBL29011286 | 0.77 | GRIN1 (0.87) | THRBCYP2C9TSHRLMNASLC22A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10004701-B2 | Methods and compositions for treating infection | UNIVERSITY OF ROCHESTER (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170065540-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | UNIVERSITY OF ROCHESTER (US) | 2017-03-09 | — | — | US | disclosed |
| US-9393221-B2 | Methods and compounds for reducing intracellular lipid storage | THE GENERAL HOSPITAL CORPORATION (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150238473-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-27 | — | — | US | disclosed |
| US-20130023488-A1 | METHODS AND COMPOUNDS FOR REDUCING INTRACELLULAR LIPID STORAGE | THE GENERAL HOSPITAL CORPORATION (US) | 2013-01-24 | — | — | US | disclosed |
| US-20100305326-A1 | Chemical Fragment Screening and Assembly Utilizing Common Chemistry for NMR Probe Introduction and Fragment Linkage | MARQUETTE UNIVERSITY (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100304998-A1 | Chemical Proteomic Assay for Optimizing Drug Binding to Target Proteins | MARQUETTE UNIVERSITY (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238473-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | MMP8, IFNG, MPO | GRIN2D 4733/4885GRIN3B 4395/4885GRIN1 4453/4885 |
| US-20100305326-A1 | Chemical Fragment Screening and Assembly Utilizing Common Chemistry for NMR Probe Introduction and Fragment Linkage | CYFIP2, RPS27A, FRS2 | GRIN2D 3960/4885GRIN3B 2632/4885GRIN1 3155/4885 |
| US-20170065540-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | MMP8, IFNG, MPO | GRIN2D 4733/4885GRIN3B 4395/4885GRIN1 4453/4885 |
| US-10004701-B2 | Methods and compositions for treating infection | MMP8, IFNG, MPO | GRIN2D 4733/4885GRIN3B 4395/4885GRIN1 4453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.